| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-44 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b688212598f50a5269dde1b7d6803c32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a96eaae8f45dd6a79f55d07b6dd58024 |
| publicationDate |
2021-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20210114219-A |
| titleOfInvention |
Biomarker composition for drug resistance diagnosis and diagnostic kit using the same |
| abstract |
The present invention is for diagnosing OXPHOS inhibitor-resistant cancer, and more particularly, to a biomarker composition for diagnosing mitochondrial electron transport chain I inhibitor drug resistance such as IM156 and rotenone used for anticancer treatment, and a diagnostic kit using the same. The present invention provides a biomarker composition comprising the MEC17 protein or a gene encoding the same, which can more easily and accurately diagnose whether a cancer patient is resistant to a corresponding drug. Through this, it is expected to be widely used in customized precision medicine by providing accurate basic information so that an appropriate alternative anticancer drug can be used in future treatment plans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023149608-A1 |
| priorityDate |
2020-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |